DUBLIN--(BUSINESS WIRE)--The "Royalty Rates in Pharmaceutical and Biotechnology Deals" report has been added to ResearchAndMarkets.com's offering. Royalty Rates in Pharmaceutical and Biotechnology ...

Dublin, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The "Protein Engineering for Pharmaceutical Biotechnology Training Course (Jan 21st - Jan 22nd, 2026)" training has been added to ResearchAndMarkets.com's ...

To help bridge that gap, Morrisville-based Kymanox Corporation has entered into a non-exclusive collaboration with Jabil Inc., which is based in St. Petersburg, Florida, to support companies ...

North Carolina, ranked in the top five states for life sciences by Business Facilities, is home to a thriving ecosystem specializing in bio and pharmaceutical manufacturing. Propelled by a low cost of ...

According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have been among the most active investors in biotech startups this year.

(MENAFN- GlobeNewsWire - Nasdaq) The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company ...